Barcelona-Berlin, 8 January 2020. ESTEVE announced today that they have come to an agreement to acquire all the shares of the German pharmaceutical company RIEMSER from Ardian, a world-leading private investment house.
Headquartered in Berlin, RIEMSER has a diversified portfolio of products with the 3 main therapeutic areas being: oncology, neurology and niche therapies. RIEMSER operates a pharmaceutical manufacturing plant in Germany and has direct geographical presence in four of Europe’s five major countries: Germany, United Kingdom, France, and Spain. Over 80% of sales come from the hospital channel, providing specialty treatments and a wide range of pharmaceuticals in therapeutic niche areas.
ESTEVE’s purchase of RIEMSER will accelerate its transformation into a specialty pharma company with more than 60% of its sales coming from proprietary products; it will also give ESTEVE access to a high-growth sector – the hospital market.
Staffan Schüberg, CEO of ESTEVE, said: "This acquisition is a meaningful contribution to our strategic path towards making ESTEVE much more of an international proprietary, specialty pharma company. RIEMSER contributes both knowledge and experience in the European hospital market, in addition to pharmaceutical activity in four of the major European markets - Germany, United Kingdom, France and Spain. RIEMSER’s presence and facilities in these geographically important markets provide a significant growth potential for ESTEVE and we will, as a combined entity with RIEMSER, continue our quest for further expansion.”
Founded in 1992, RIEMSER was acquired in 2012 by Ardian with the goal to focus the company’s activities on its core specialty pharma business and expand the company internationally. Under the ownership of Ardian, RIEMSER has enjoyed impressive international growth through acquisitions, first in France, then in the UK and more recently in Spain, and it has strengthened its portfolio of specialty products by purchasing several products from large multinational pharmaceutical firms.
Konstantin von Alvensleben, CEO of RIEMSER, said: "We are very proud that with ESTEVE, a strong family-owned pharma company with a long tradition has chosen to acquire RIEMSER. Together we will build on our strengths and leverage our profile as a European specialty pharma company with proprietary products and hospital focus to further increase our international reach and expand our business. At the same time, we want to thank Ardian for their support over the past years. "
The acquisition is expected to be completed within Q1 2020. The parties have agreed not to disclose any details of the transaction.
RIEMSER Pharma GmbH (www.riemser.com) was established in 1992 and originated from the Friedrich Löffler Institute on Riems Island (Greifswald). RIEMSER has been in business for more than 25 years, during which time it has evolved from being a manufacturer of veterinary medicines to a successful provider of specialty pharmaceuticals for therapeutic niches in the field of human medicine.
RIEMSER sells, licenses, markets and distributes pharmaceutical products. Over 400 approvals worldwide, of which 28 were granted in the last three years, stand testament to the special expertise of RIEMSER for the approval and opening of new markets for pharmaceutical products.
The product range specifically covers prescription drugs used to treat serious diseases in the therapeutic areas of oncology, infectiology, neurology, cardiovascular, dermatology, and rheumatology, as well as the treatment of tuberculosis, obesity and primary axillary hyperhidrosis. Medicinal products and food supplements complement the portfolio.
Besides its international group headquarters in Berlin, the company has three other locations in Germany. In 2014 and 2015, RIEMSER acquired the subsidiaries Keocyt based in France and Intrapharm based in England. Since October 2019, RIEMSER is also present in Spain through its subsidiary RIEMSER Iberia. In addition, it has established an international distribution network. RIEMSER is a portfolio company of Ardian, one of the world’s leading private investment companies.
ESTEVE (www.ESTEVE.com) is a global pharmaceutical company based in Barcelona (Spain). Its mission is to advance innovation in order to improve people’s lives. Since its foundation in 1929, its focus has been to provide solutions for unmet medical needs. With a team of around 2,300 people, ESTEVE has an important presence in Europe, the United States, Mexico, and China. In 2018, it achieved a turnover of €758 million.
The company offers solutions in the pharmaceutical segment, mainly in Spain with a broad and highly innovative product portfolio and as a global Contract Manufacturing Organization (CMO). ESTEVE is at present advancing in its transformation journey to become an international proprietary specialty pharmaceutical company.
Ardian (www.ardian.com) is a world-leading private investment house with assets of US$96bn managed or advised in Europe, the Americas and Asia. The company is majority-owned by its employees. It keeps entrepreneurship at its heart and focuses on delivering excellent investment performance to its global investor base.
Through its commitment to shared outcomes for all stakeholders, Ardian’s activities fuel individual, corporate and economic growth around the world.
Holding close its core values of excellence, loyalty and entrepreneurship, Ardian maintains a truly global network, with more than 640 employees working from fifteen offices across Europe (Frankfurt, Jersey, London, Luxembourg, Madrid, Milan, Paris and Zurich), the Americas (New York, San Francisco and Santiago) and Asia (Beijing, Singapore, Tokyo and Seoul). It manages funds on behalf of more than 1,000 clients through five pillars of investment expertise: Fund of Funds, Direct Funds, Infrastructure, Real Estate and Private Debt.
Press contact for ESTEVE:
Maria Angels Valls
Phone: +34 934466000, +34 696474724
Press contact for RIEMSER:
Charles Barker Corporate Communications
Jan P. Sefrin
Phone +49 69 794090-26
Press contact for ARDIAN:
Charles Barker Corporate Communications
Phone +49 69 794090-24